Dossier assessment

Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-21
Last updated

Report documents

  1. Extract of dossier assessment

    Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 635 kB, EN, not accessible
  2. Dossier assessment

    Baloxavir marboxil (influenza) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 873 kB, DE, not accessible

Dossier assessment

Indication:

Patients aged 12 years and above with uncomplicated influenza

Result of dossier assessment:

Without risk of influenza-related complications: added benefit not proven.

If there is an increased risk of a severe course of the disease: added benefit not proven.

Project details

Project no.
A21-21
Commission
Commission awarded on 12.02.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Baloxavir marboxil (influenza - post-exposure prophylaxis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-22
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form